Ectoin® Mouth Wash (EML03) in the Prevention & Treatment of

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This prospective non-interventional comparator study is to collect data on the clinical effectiveness and compliance of Ectoin® Mouth Wash solution (EML03) and to proof superiority to a well-established medical device on the market in the prevention of radiation-induced mucositis. The study doesn´t intervene with routine treatment strategy.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04308161` - Vitamin D Oral Gel for Prevention of Radiation Induced Oral Mucositis	Phase 2
	Completed	`NCT03988556` - Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis	N/A

NCT number	NCT03932292
Study type	Interventional
Source	Bitop AG
Contact
Status	Completed
Phase	N/A
Start date	December 18, 2018
Completion date	November 5, 2019

Ectoin® Mouth Wash (EML03) in the Prevention and Treatment of Radiation-induced Oral Mucositis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms